Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1668-1673

  Kornek, G V ^a   Haider, K ^b   Kwasny, W ^b   Hejna, M ^a   Raderer, M ^a   Meghdadi, S ^a   Burger, D ^c   Schneeweiss, B ^a   Depisch, D ^b   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b General Hospital of WrNeustadt   (Austria)

^c KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

Advanced breast cancer; Human granulocyte colony stimulating factor; Mitomycin C; Vinorelbine

Indexed keywords

ANTINEOPLASTIC AGENT; MITOMYCIN C; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BOLUS INJECTION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 10544241961     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.607     Document Type: Article

References (32)

1. ANDERSON JR, BERNSTEIN L AND PIKE MC. (1982). Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics, 38, 407-416.
2. AYASH LJ, ELIAS A, WHEELER C, REICH E, SCHWARTZ G, MAZANET R, TEPLER I, WARREN D, LYNCH C, GONIN R, SCHNIPPER L, FREI E AND ANTMAN K. (1994). Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor support for metastatic breast cancer: a feasibility study. J. Clin. Oncol., 12, 37-44.
3. BINET S, CHAINEAU E, FELLOUS A, LATASTE H, KRIKORIAN A, COUZINIER JP AND MEININGER V. (1990). Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int. J. Cancer, 46, 262-266.
4. BONADONNA G, VALLAGUSSA P, MOLITERNI A, ZAMBANETTI M AND BRAMBILLA C. (1995). Adjuvant cyclophosphamide, methotrexate and fluorouracil in node positive breast cancer: the results of 20 years follow-up. N. Engl. J. Med., 14, 332-341.
5. CANNOBIO L, BOCCARDO F, PASTORINI G, BREMA F, MARTINI C, RESASCO M AND SANTI L. (1989). Phase II study of navelbine in advanced breast cancer. Semin. Oncol., 16, 33-36.
6. CHEVALLIER B, FUMOLEAU P, KERBRAT P, DIERAS V, ROCHE H, KRAKOWSKI I, AZLI N, BAYSSAS M, LENTZ MA AND VAN GLABBEKEN M. (1995). Doxetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol., 13, 314-322.
7. CLAVEL M AND CATIMEL G. (1993). Breast cancer: chemotherapy in the treatment of advanced disease. Eur. J. Cancer, 29A, 598-604.
8. DEGARDIN M, BONNETERRE J, HECQUET B, PION JM, ADENIS A, HORNER D AND DEMAILLE A. (1994). Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann. Oncol., 5, 423-426.
9. DEN HARTIG J, VERWEIJ AND PINEDO HM. (1995). Mitomycin C. In Cancer Chemotherapy, Pinedo HM and Chabner BA. (eds), Annual 7, pp. 83-90. Elsevier: Amsterdam.
10. FABI A, TONACHELLA R, SAVARESE A, CIRULLI S, TOMAO S, CONTE E AND COGNETTI F. (1995). A phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann. Oncol., 6, 187-189.
11. FALKSON GF, GELMAN R, FALKSON CI, CLICK J AND HARRIS J. (1991). Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study. J. Clin. Oncol., 9, 2153-2161.
12. FUMOLEAU P, DELGADO FM, DELOZIER T, MONNIER A, GIL DELGADO MA, KERBRAT P, GARCIA-GIRALT E, KEILING R, NAMER M, CLOSON MT, GOUDIER MJ, CHOLLET P, LECOURT L AND MONTCUQUET P. (1994). Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J. Clin. Oncol., 11, 1245-1252.
13. GARCIA-CONDE J, LLUCH A, CASADO A, GERVASIO H, DE OLIVEIRA C, DE PABLO JL, GOROSTIAGA J, GIRON GC, CERVANTES A, MARTINEZ A, PEZOUS N, DELGADO FM AND DIAZ RUBIO E. (1992). Phase II trial with navelbine in advanced breast cancer. Breast Cancer Res. Treat., 23, 143-145.
14. GASPARINI G, CAFFO O, BARNI S, FRONTINI L, TESTOLIN A, GUGLIELMI RB AND AMBROSINI G. (1994). Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J. Clin. Oncol., 12, 2094-2101.
15. HOHNEKER JA. (1994). A summary of vinorelbine (navelbine) safety data from North American clinical trials. Semin. Oncol., 21 (suppl. 10), 42-47.
16. HOLMES FA, WALTERS RS, THERIAULT RL, FORMAN AD, NEWTON LK, RABER MN, BUZDAR AU, FRYE DK AND HORTOBAGYI GN. (1991). Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl Cancer Inst., 83, 1797-1805.
17. HORTOBAGYI GN. (1993). Mitomycin C, its evolving role in the treatment of breast cancer. Oncology, 50 (suppl. 1), 1-8.
18. KORNEK GV, RADERER M, DEPISCH D, HAIDER K, FAZENY B, DITTRICH C AND SCHEITHAUER W. (1994). Amonafide as first-line chemotherapy for metastatic breast cancer. Eur. J. Cancer, 30A, 398-400.
19. LUEDKE D, MCLAUGHLIN TT, DAUGHADAY C, DAUGHADAY C, LUEDKE S, HARRISON B, REED G AND ORLANDO M. (1985). Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer, 55, 542-545.
20. MANGENEY P, ANDRIAMIALISOA RZ AND LALLEHAND JY. (1979). 5′-Noranhydro-vinblastine. Prototype of a new class of vinblastine derivatives. Tetrahydron, 35, 2175-2179.
21. MILLER AB, HOOGSTRATEN B AND STAQUET M. (1981). Reporting results of cancer treatment. Cancer, 147, 207-214.
22. NOLE F, DE BRAUD F, DE PAS M, CASTAGNA L, COVELLI A AND AAPRO S. (1995). A phase I study of navelbine and fluorouracil plus folinic acid in patients with metastatic breast cancer (abstract 431). In Proceedings of the 5th International Cancer Congress on Anticancer Chemotherapy, Paris. 31 Jan 3 Feb.
23. POUILLART P, HOANG HT, BRUGERIE E AND LHERITER J. (1974). Sequential administration of two oncostatic drugs: studies of modalities for pharmacodynamic potentiation. Biomedicine, 21, 471-479.
24. REICHMAN BS, SEIDMAN AD, CROWN JPA, HEELAN R, HAKES TB, LEBWOHL DE, GILEWSKI TA, SURBONE A, CURRIE V, HUDIS CA, YAO TJ, KLECKER R, JAMIS-DOW C, COLLINS J. QUINLIVAN S, BERKERY R, TOOMASI F, CANETTA R, ISHERMAN J, ARBUCK S AND NORTON J. (1993). Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J. Clin. Oncol., 11, 1943-1951.
25. ROMERO A, RABINOVICH MG, VALLEJO CT, PEREZ JE, RODRIGEZ R, CUEVAS MA, MACHIAVELLI M, LACAVA JA, LANGHI M, ROMERO ACUNA L, AMATO S, BARIERI R, SABATINI C AND LEONE BA. (1994). Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J. Clin. Oncol., 12, 336-341.
26. ROWINSKY EK, CAZENAVE LA AND DONEHOWER RC. (1990). Taxol: a novel investigational antimicrotubule agent. J. Natl Cancer Inst., 82, 1247-1259.
27. SCHEITHAUER W, DITTRICH C, KORNEK GV, HAIDER K, LINKESCH W, GISSLINGER H AND DEPISCH D. (1991). Phase II study of amonafide in advanced breast cancer. Breast Cancer Res. Treat., 20, 63-67.
28. SCHEITHAUER W, KORNEK GV, HAIDER K, KWASNY W, SCHENK T, PIRKER R AND DEPISCH D. (1993). Effective second-line chemotherapy for advanced breast cancer with navelbine and mitomycin C. Breast Cancer Res. Treat., 26, 49-53.
29. SORENSEN JB. (1995). Current position of vinorelbine in cancer chemotherapy. Ann. Oncol., 6, 105-107.
30. SPIELMANN M, DORVAL T, TURPIN F, ANTOINE E, JOUVE M, MAYLEVIN F, LACOMBE D, ROUSSE J, POUILLART P, TURSZ T AND MERLE S. (1994). Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J. Clin. Oncol., 12, 1764-1770.
31. TOUSSAINT C, IZZO J, SPIELMANN M, MERLE S, MAY-LEVIN F, ARMAND JP, LACOMBE D, TURSZ T, SUNDERLAND M, CHABOT GG AND CVITKOVIC E. (1994). Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J. Clin. Oncol., 12, 2102-2112.
32. VALAGUSSA P, BONADONNA G AND VERONESI A. (1978). Patterns of relapse and survival following radical mastectomy. Cancer, 41, 1170-1172.